Abstract
Oxytocin is a nonapeptide mammalian hormone, best known for its role in childbirth, parturition and lactation. It has been implicated in the control of social behaviors and relationships, such as monogamy or promiscuous behaviors. The putative involvement of oxytocin in schizophrenia was first postulated following several pioneer reports of oxytocin use in schizophrenia and observations of increased oxytocin levels in the cerebrospinal fluid of schizophrenic patients, although this latter finding has subsequently been challenged. More recently, oxytocin plasma levels have been found to be decreased in schizophrenic individuals, particularly in those exhibiting hyponatremic polydipsia and emotional dysregulation. Some authors report that intranasal oxytocin administration to schizophrenic patients may reduce symptomatology. The aim of the present paper was to review studies investigating symptomatology, social cognition and emotion recognition changes in DSM-IV-TR schizophrenic patients, after administration of intranasal oxytocin at different doses. Literature search was conducted in March, 2012. PubMed and Scopus databases were used to find studies for inclusion in the systematic review. Oxytocin may represent an important novel adjunctive treatment for patients with schizophrenia. However, some limitations of current studies cannot be overlooked and further investigations are certainly needed.
Keywords: Intranasal oxytocin, schizophrenia, social cognition, emotions, review.
CNS & Neurological Disorders - Drug Targets
Title:The Role of Intranasal Oxytocin in the Treatment of Patients with Schizophrenia: A Systematic Review
Volume: 12 Issue: 2
Author(s): Domenico De Berardis, Stefano Marini, Felice Iasevoli, Carmine Tomasetti, Andrea de Bartolomeis, Monica Mazza, Alessandro Valchera, Michele Fornaro, Marilde Cavuto, Venkataramanujam Srinivasan, Gianna Sepede, Giovanni Martinotti and Massimo Di Giannantonio
Affiliation:
Keywords: Intranasal oxytocin, schizophrenia, social cognition, emotions, review.
Abstract: Oxytocin is a nonapeptide mammalian hormone, best known for its role in childbirth, parturition and lactation. It has been implicated in the control of social behaviors and relationships, such as monogamy or promiscuous behaviors. The putative involvement of oxytocin in schizophrenia was first postulated following several pioneer reports of oxytocin use in schizophrenia and observations of increased oxytocin levels in the cerebrospinal fluid of schizophrenic patients, although this latter finding has subsequently been challenged. More recently, oxytocin plasma levels have been found to be decreased in schizophrenic individuals, particularly in those exhibiting hyponatremic polydipsia and emotional dysregulation. Some authors report that intranasal oxytocin administration to schizophrenic patients may reduce symptomatology. The aim of the present paper was to review studies investigating symptomatology, social cognition and emotion recognition changes in DSM-IV-TR schizophrenic patients, after administration of intranasal oxytocin at different doses. Literature search was conducted in March, 2012. PubMed and Scopus databases were used to find studies for inclusion in the systematic review. Oxytocin may represent an important novel adjunctive treatment for patients with schizophrenia. However, some limitations of current studies cannot be overlooked and further investigations are certainly needed.
Export Options
About this article
Cite this article as:
Berardis Domenico De, Marini Stefano, Iasevoli Felice, Tomasetti Carmine, Bartolomeis Andrea de, Mazza Monica, Valchera Alessandro, Fornaro Michele, Cavuto Marilde, Srinivasan Venkataramanujam, Sepede Gianna, Martinotti Giovanni and Giannantonio Massimo Di, The Role of Intranasal Oxytocin in the Treatment of Patients with Schizophrenia: A Systematic Review, CNS & Neurological Disorders - Drug Targets 2013; 12 (2) . https://dx.doi.org/10.2174/1871527311312020012
DOI https://dx.doi.org/10.2174/1871527311312020012 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of Biologically Active Ingredients from Chinese Herbal Medicines in the Regulation of Autophagy in Treating Cardiovascular Diseases and Other Chronic Diseases
Current Pharmaceutical Design (±)-3,5-Bis(substitutedmethyl)pyrrolidines: Application to the Synthesis of Analogues of glycine-L-proline-L-glutamic Acid (GPE)
Current Organic Synthesis A Comparison Between Quetiapine and Aripiprazole for Treatment of Schizophrenia: A Double Blind Contrast
Current Psychopharmacology TNF-α Inhibitors with Anti-Oxidative Stress Activity from Natural Products
Current Topics in Medicinal Chemistry ApoE ε4 Allele Related Alterations in Hippocampal Connectivity in Early Alzheimer’s Disease Support Memory Performance
Current Alzheimer Research Induced Pluripotent Stem Cell-Based Studies of Parkinson's Disease: Challenges and Promises
CNS & Neurological Disorders - Drug Targets Medicinal Agents and Metabolic Syndrome
Current Medicinal Chemistry Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Sleep, Depression and Insomnia – A Vicious Circle?
Current Psychiatry Reviews Pharmacological Intervention at Ionotropic Glutamate Receptor Complexes
Current Pharmaceutical Design Discovery of ADDL-Targeting Small Molecule Drugs for Alzheimers Disease
Current Alzheimer Research Meet Our Editorial Board Member
Current Alzheimer Research Hyperhomocysteinemia in Movement Disorders: Current Evidence and Hypotheses
Current Vascular Pharmacology Amyloid-Binding Compounds and their Anti-Prion Potency
Current Topics in Medicinal Chemistry Unraveling the Action Mechanism of Buyang Huanwu Tang (BYHWT) for Cerebral Ischemia by Systematic Pharmacological Methodology
Combinatorial Chemistry & High Throughput Screening Brain MRI, SPECT and PET in Early Alzheimer’s Disease: A Minor Mismatch between Volumetric and Functional Findings
Current Molecular Imaging (Discontinued) Advantages of Structure-Based Drug Design Approaches in Neurological Disorders
Current Neuropharmacology Glycogen Synthase Kinase-β3 in Ischemic Neuronal Death
Current Neurovascular Research Proposing a “Lipemic Index” As a Nutritional and Research Tool
Current Vascular Pharmacology DLPF Targeted Repetitive Transcranial Magnetic Stimulation Improves Brain Glucose Metabolism Along with the Clinical and Electrophysiological Parameters in CBD Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets